Get to know our clinical trials
Ensayo clínico para evaluar la eficacia y seguridad de AP-325 en pacientes con dolor neuropático periférico post-quirúrgico
THE AIM OF THIS STUDY IS TO INVESTIGATE WHETHER THE NEWLY DEVELOPED DRUG AP-325 CAN REDUCE NEUROPATHIC PAIN IN PATIENTS SUFFERING FROM ONGOING NEURALGIA (NEUROPATHIC PAIN) AFTER BREAST, THORACIC, ABDOMINAL, VARICOSE VEIN, GYNECOLOGICAL OR INGUINAL HERNIA REPAIR SURGERY. IN ADDITION, HOW EACH PATIENT TOLERATES AP-325 WILL BE INVESTIGATED AND THE AP-325 BLOOD CONCENTRATION WILL BE MEASURED.
Technical Summary
- PARALLEL-GROUP, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AP-325 IN PATIENTS WITH POST-SURGICAL PERIPHERAL NEUROPATHIC PAIN.
- Code EudraCT: 2019-003502-28
- Protocol number: AP-325.04
- Promoter: Algiax Pharmaceutical
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.